English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Conclusions 1.Sollner W, DeVries A, Steixner E, Lukas P, Sprinzl G, Rumpold G & Maislinger S (2001) How successful are oncologists in identifying patient distress, perceived social support, and the need for psychosocial counselling? British Journal of Cancer, 84(2): 179-185 2.Sonino N, Ruini C, Navarrini C et al. Psychological Impairment in patients treated for pituitary disease: a controlled study. Clinical Endocrinology. 2007; 67(5): 719-26. 3.Webb S, Prieto L, Badia X et al. Acromegaly quality of life questionnaire (AcroQoL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clinical Endocrinology. 2002; 57(2): 251-8. 4.Webb S, Badia X & Surinach N. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. European Journal of Endocrinology. 2006; 155(2): 269-77. 5.Webb S, Badia X, Barahona M et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. European Journal of Endocrinology. 2008; 158(5): 623-30. 6.Lovas K, Curran S, Oksnes M et al. Development of a disease-specific quality of life questionnaire in Addison’s disease. Journal of Clinical Endocrinology and Metabolism. 2009; 95(2): 545-51. Pituitary tumours, though almost always benign, are now included with other central nervous system tumours in cancer services. It therefore seems appropriate to adapt this oncology tool for use with pituitary patients. • Research has shown that high levels of patient distress may not be identified during consultations with healthcare professionals (HCPs), resulting in significant patient dissatisfaction with care and additional use of primary and secondary care services[1].

Developing a pituitary distress thermometer (PDT) - a means to improve patient quality of life